Vertex Pharmaceuticals Inc (VRTX) - Total Liabilities
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has total liabilities worth $6.98 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Vertex Pharmaceuticals Inc cash conversion from operations to assess how effectively this company generates cash.
Vertex Pharmaceuticals Inc - Total Liabilities Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check VRTX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Vertex Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DBS GROUP ADR/4 SD 1
F:DEV
|
Germany | €828.57 Billion |
|
GlaxoSmithKline plc
MX:GSKN
|
Mexico | MX$45.59 Billion |
|
Crowdstrike Holdings Inc
NASDAQ:CRWD
|
USA | $6.61 Billion |
|
Air Liquide SA
PA:AI
|
France | €24.97 Billion |
|
State Bank of India
NSE:SBIN
|
India | Rs72.70 Trillion |
|
Lockheed Martin Corporation
NYSE:LMT
|
USA | $54.09 Billion |
|
Bank of Montreal
TO:BMO
|
Canada | CA$1.37 Trillion |
|
Sanofi
F:SNW2
|
Germany | €56.26 Billion |
Liability Composition Analysis (1990–2025)
This chart breaks down Vertex Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VRTX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vertex Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vertex Pharmaceuticals Inc (1990–2025)
The table below shows the annual total liabilities of Vertex Pharmaceuticals Inc from 1990 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.98 Billion | +13.94% |
| 2024-12-31 | $6.12 Billion | +18.91% |
| 2023-12-31 | $5.15 Billion | +21.51% |
| 2022-12-31 | $4.24 Billion | +27.18% |
| 2021-12-31 | $3.33 Billion | +8.73% |
| 2020-12-31 | $3.06 Billion | +37.25% |
| 2019-12-31 | $2.23 Billion | +23.34% |
| 2018-12-31 | $1.81 Billion | +20.42% |
| 2017-12-31 | $1.50 Billion | -3.34% |
| 2016-12-31 | $1.56 Billion | +10.77% |
| 2015-12-31 | $1.40 Billion | +13.39% |
| 2014-12-31 | $1.24 Billion | +28.66% |
| 2013-12-31 | $962.64 Million | -36.87% |
| 2012-12-31 | $1.52 Billion | +23.10% |
| 2011-12-31 | $1.24 Billion | +1.42% |
| 2010-12-31 | $1.22 Billion | +42.17% |
| 2009-12-31 | $859.14 Million | +15.85% |
| 2008-12-31 | $741.61 Million | +124.60% |
| 2007-12-31 | $330.18 Million | -20.56% |
| 2006-12-31 | $415.64 Million | +34.16% |
| 2005-12-31 | $309.82 Million | -39.25% |
| 2004-12-31 | $510.01 Million | -4.05% |
| 2003-12-31 | $531.57 Million | +21.60% |
| 2002-12-31 | $437.14 Million | -2.81% |
| 2001-12-31 | $449.78 Million | +5.30% |
| 2000-12-31 | $427.12 Million | +1740.18% |
| 1999-12-31 | $23.21 Million | +15.48% |
| 1998-12-31 | $20.10 Million | +2.55% |
| 1997-12-31 | $19.60 Million | +54.33% |
| 1996-12-31 | $12.70 Million | -7.30% |
| 1995-12-31 | $13.70 Million | +28.04% |
| 1994-12-31 | $10.70 Million | -6.96% |
| 1993-12-31 | $11.50 Million | +61.97% |
| 1992-12-31 | $7.10 Million | +44.90% |
| 1991-12-31 | $4.90 Million | +22.50% |
| 1990-12-31 | $4.00 Million | -- |
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age a… Read more